Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin.
Erythropoietin (Epo) decreases neuronal injury and cell death in vitro and in vivo. To lay the groundwork for use of Epo as a potential therapy for brain injury, we tested the hypothesis that systemic dosing of high-dose recombinant Epo (rEpo) would result in neuroprotective rEpo concentrations in the spinal fluid of adult and developing animals. This report characterizes the pharmacokinetics of high-dose rEpo in the blood and spinal fluid of juvenile and adult nonhuman primates (n = 7) and fetal sheep (n = 37) following a single injection. Timed blood and spinal fluid samples were collected following rEpo injection. Epo accumulation in spinal fluid was dependent on peak serum concentration and time following injection. We demonstrate that high-dose rEpo was well tolerated and results in neuroprotective concentrations in spinal fluid of adult and developing animal models by 2-2.5 h after injection.
Juul
Sandra E
SE
Department of Pediatrics, University of Washington, Seattle, Wash. 98195, USA. sjuul@u.washington.edu
McPherson
Ronald J
RJ
Farrell
Francis X
FX
Jolliffe
Linda
L
Ness
Dana J
DJ
Gleason
Christine A
CA
D000375:Aging / Q000097:blood / Q000378:metabolism*; D000818:Animals; D001812:Blood-Brain Barrier; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000008:administration & dosage* / Q000097:blood / Q000134:cerebrospinal fluid*; D005312:Fetal Blood; D005333:Fetus / Q000378:metabolism*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008254:Macaca nemestrina; D008297:Male; D009994:Osmolar Concentration; D011994:Recombinant Proteins; D012756:Sheep
D011994:Recombinant Proteins; D004921:Erythropoietin